disability (ID). We report clinical, genetic, and molecular findings in 4 patients with typical XLOS dysmorphic features belonging to 2 unrelated families. Two novel pathogenic lossof-function MID1 variants, a maternally inherited c.1656del and a de novo c.1215_1228dup, were identified. Subsequently, we performed a genotype-phenotype analysis using data from 91 male XLOS patients. To test the mutation impact on the phenotype; the type of mutation, the MID1-impaired domain and function were compared with the presence of each of the major clinical features (hyperKeywords Genotype-phenotype correlation · MID1 pathogenic variants · X-linked Opitz G/BBB syndrome Abstract X-linked Opitz G/BBB syndrome (XLOS) is a multisystemic congenital condition, caused by mutations in the midline-1 gene ( MID1 ), characterized by a large inter-and intrafamilial phenotypic variability and often associated with intellectual 
Opitz G/BBB syndrome is a multiple midline congenital condition recognizable by minor facial anomalies such as telecanthus/hypertelorism, a broad nasal bridge, and clefts of the lip and/or palate (CLP). Other midline features include congenital heart defect, imperforate anus, hypospadias, malformations of the central nervous system (including hypoplasia of the corpus callosum and agenesis of cerebellar vermis), laryngo-tracheo-esophageal (LTE) defects, and intellectual disability/developmental delay (ID/DD) [Fontanella et al., 2008] . The disorder can be inherited in an X-linked (OMIM 300000) or autosomal dominant (OMIM 145410) manner [Robin et al., 1995; Kruszka et al., 2015] . The X-linked form, Xlinked Opitz G/BBB syndrome (XLOS), is caused by pathogenic variants in the midline-1 gene ( MID1 -OMIM * 300552) located in the short arm of the X chromosome (Xp22.2). MID1 spans 400 kb and is composed of 10 exons which encode a 667-amino acid protein belonging to the tripartite motif subfamily of zinc finger proteins [Quaderi et al., 1997] . XLOS shows variable penetrance particularly in female carriers who can be mildly affected, presenting with hypertelorism or, more rarely, other clinical features such as short uvula or lack of an incisor, and CLP. The extensive inter-and intrafamilial phenotypic variability is yet to be explained [Preiksaitiene et al., 2015] .
To date, 90 different pathogenic variants in MID1 have been described, including missense and nonsense mutations, small insertions and deletions, splice site alterations, exon deletions and duplications as well as deletions of the complete gene [Quaderi et al., 1997; Gaudenz et al., 1998; Schweiger et al., 1999; Cox et al., 2000; De Falco et al., 2003; Winter et al., 2003; Pinson et al., 2004; So et al., 2005; Cho et al., 2006; Mnayer et al., 2006; Shaw et al., 2006; Ferrentino et al., 2007; Fontanella et al., 2008; Hsieh et al., 2008; Taylor and Aftimos, 2010; Ruiter et al., 2010; Zhang et al., 2011; Hu et al., 2012; Huning et al., 2013; Migliore et al., 2013; Ji et al., 2014; Preiksaitiene et al., 2015] . MID1 consists of the RING finger (RING), zinc-binding B-box-1 (B1) and B-box-2 (B2) domains, followed by a coiled-coil region (CC) and C-terminal subgroup one signature (COS), fibronectin type III repeat (FN3) and PRY-SPRY domains [Quaderi et al., 1997; Du et al., 2014] . Functionally impaired MID1 variants have a lower affinity for microtubules, causing degradation of protein phosphatase 2A (PP2A), a microtubule-associated protein. Controlling PP2A is essential for proper hippocampus development, and PP2A absence seems to have a direct impact on the core-midline phenotype observed in XLOS patients [Trockenbacher et al., 2001; Schweiger and Schneider, 2003 ]. Furthermore, a protein complex including MID1 is involved in mRNA transport and translation by interacting with several proteins, such as elongation factor I alpha, RACK1, Annexin A2, and proteins of the small ribosomal subunits [Aranda-Orgillés et al., 2008 . Some authors found associations between impaired MID1 B-box domains and frequent anomalies, or between variants in the FN3 domain and milder phenotypes. However, these results were not confirmed in other recent studies where more patients were included .
We performed a genotype-phenotype analysis by using data from 91 XLOS index patients, aiming to investigate the prevalence of the associated clinical features to assist in establishing a proper prognosis and disease management, and ultimately increase our understanding of the mechanisms of disease.
Case Report
In family A, patients presented with hypertelorism, telecanthus, and anteverted nostrils. The proband, A-III:3, also had CLP, hypospadias, and swallowing difficulties, necessitating a tracheotomy which was removed at 4 years of age. Furthermore, the boy also showed mild early global DD with no learning difficulties and a normal IQ value at the age of 7 years. His maternal cousins, A-III:1 and A-III:2, showed low-set and dysplastic ears besides hypertelorism, telecanthus, and anteverted nostrils. The cousins had a normal IQ and A-III:1 also had hypospadias. Both mothers had hypertelorism. In family B, the proband, B-II:1, presented with hypertelorism, telecanthus, anteverted nostrils, abnormal ears, inverted nipples, and hypospadias. This boy's psychomotor development and IQ were normal ( Fig. 1 ; Table 1 ). His mother (I:2) showed normal facial features with no hypertelorism.
Methods and Results
In 4 XLOS male individuals belonging to 2 unrelated families, 2 novel MID1 variants were characterized by Sanger sequencing analysis of all exons and respective flanking regions of the gene (online suppl. Fig. 1 (GeneSplicer 12.13, MaxEnt 12.38, HSF 94.37) . The proband's maternal cousins, A-III:1 and A-III:2, are hemizygous for the same MID1 pathogenic variant. His mother (II:6) and maternal aunt (II:1) are both heterozygous for the pathogenic variant. Regarding the deceased brothers, one was a stillbirth, and the other brother died at 19 months due to an unclassified "disorder." In both cases, the presence of major anomalies was not mentioned. Both maternal grandfather and grandmother had several brothers and sisters with healthy offspring.
In family B, a frameshift MID1 variant was identified in patient B-II:1: c.1215_1228dup, p.(Ser410Thrfs * 34). years old) also present with low-set and dysplastic ears. The proband of family B, B-II:1 (left picture: 6 months old; right picture: 3 years old), has hypertelorism, telecantus, anteverted nostrils, and abnormal ears.
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This genetic alteration was not present in his mother's (I:2) blood or saliva DNA samples (saliva was collected by Oragene ® DNA Self-Collection kit, DNA Genotek, Ottawa, ON, Canada). To confirm the correct identification of the samples and their familial relationship, 28 short tandem repeats, AMELX and ZFX genes (Devyser Complete v2 QF-PCR kit, Devyser AB, Hägersten, Sweden) were used (online suppl. Fig. 1 Toral-Lopez et al., 2012] are clearly distinct from our patient's clinical outcome and the mosaic mutation occurs only in a low percentage of white blood cells, the contribution of the chromosome 21 monosomy to the phenotype was considered to be minor. Assessment of the X-chromosome inactivation pattern was done by using a Humara assay [Allen et al., 1992] in the peripheral blood DNA of the patient's mother (I:2; online suppl. Fig. 1 ). In accordance with previously published criteria, X-chromosome inactivation ratios of less than or equal to 80: 20 were considered "random," and ratios greater than 90: 10 were considered "highly skewed" [Amos-Landgraf et al., 2006] . No significant skewing (>80: 20) was detected in any of the 3 samples analyzed. 49 management options. Therefore, we performed a review of the previously published 103 index male XLOS patients and described 2 in this study ( Fig. 2 ; online suppl. Table 1) . One hundred and five index cases out of 139 XLOS patients were selected for analysis to ensure independent observations. Fourteen cases were excluded from further analyses (for details see online suppl. information). Therefore, only 91 XLOS index patients (80 different variants) were considered. In this subgroup of patients, only 22 had information regarding the complete phenotype. The remaining patients included cases with absent information on: structural brain ( n = 68), and anal defects ( n = 58), ID/DD ( n = 52), heart defects (n = 49), LTE defects ( n = 37), CLP ( n = 29), hypospadias ( n = 17), and hypertelorism ( n = 13). To test the mutation impact on the phenotype, several variables were compared with the presence of each of the major and minor clinical features. The variables tested included the type of mutation, protein domains affected by the mutation, presence of a loss-of-function mutation changing transcript size, and mutations that disrupt protein regions with a known biological role. Association between variables was performed using Pearson χ 2 test and Fisher exact test, SPSS for Windows, version 23 (IBM-SPSS, Chicago, IL, USA). A p value of <0.05 was considered statistically significant. Correction for multiple testing was performed using the Bonferroni test [Bonferroni, 1935] .
The types of MID1 pathogenic variants include premature stop codon (44/92; 47.8%), followed by amino acid changes (23/92; 25.0%), and putatively splicing defects (13/92; 14.1%). XLOS major clinical features (present in ≥ 50% of the patients) are hypertelorism (89/90; We did not observe an association between the presence of any of the clinical features assessed and the affected MID1 domains: RING, B1, B2, CC, COS, FN3, PRY, and SPRY (hypertelorism p = 1.451, hypospadias p = 1.462, LTE defects p = 1.558, CLP p = 1.513, ID/DD p = 1.642, structural anal p = 0.609, heart p = 0.256, and brain defects p = 0.256), nor frequencies of any mutation type (hypertelorism p = 1.451, hypospadias p = 1.462, LTE defects p = 1.558, CLP p = 1.513, ID/DD p = 1.642, structural anal p = 0.176, heart p = 0.354, and brain defects p = 0.193). There was also no association between the frequency of loss-of-function mutations affecting all transcripts and those affecting only longer transcripts in patients with any of the XLOS clinical features (hypertelorism p = 1.624, hypospadias p = 1.642, LTE defects p = 1.757, CLP p = 1.730, ID/DD p = 1.905, structural anal p = 0.445, heart p = 0.880, and brain defects p = 0.653). Finally, we addressed a potential genotype-phenotype association between the 2 MID1 regions with a well-characterized biological role, ubiquitination and microtubules interaction, and XLOS clinical features (hypertelorism p = 1.451, hypospadias p = 1.462, LTE defects p = 1.558, CLP p = 0.661, ID/DD p = 0.609, structural anal p = 0.741, brain p = 0.698, and heart defects p = 0.032). The observed association between heart defects and MID1 function ( p = 0.032) was classified as not significant after correction for multiple testing (Bonferronicorrected p = 0.128). Our findings expand the clinical and molecular spectrum of MID1 and do not show any significant genotype-phenotype correlation.
Discussion
Two novel frameshift pathogenic variants, c.1656del and c.1215_1228dup, presumably resulting in a premature stop codon p.(Trp552Cysfs * 35)/r.(spl?) and p.(Ser410Thrfs * 34), respectively, were identified in 4 patients. The X-chromosome inactivation patterns in the blood of unaffected carrier females were not skewed, which is in concordance with previously published data [Pinson et al., 2004] and may explain the hypertelorism in carrier mothers (family A: II:1 and II:6). None of the 4 male XLOS patients have a neurodevelopmental or intellectual disability. Although XLOS is defined as an ID syndrome, this complies with previously reported patients without ID.
Our analyses suggest that there is no correlation between specific major or minor clinical signs and any of the tested variables. This confirms the data of Li et al. [2015] . However, some data due to incomplete phenotyping or relatively poorly described clinical details of patients with XLOS are missing (i.e., full IQ assessment is often missing). Fontanella et al. [2008] suggested an association between truncating mutations (frameshift and nonsense) and the presence of assessed brain deformities (11 out of 12 cases). In the same study, a possible association between CLP abnormalities and mutations affecting splicing of MID1 transcripts was observed. These results could not be confirmed in our study.
Further studies involving more detailed phenotyping in a larger cohort, integrating the data from familial cases, are required to explore the role of specific pathogenic variants in the genesis of this disorder. Therefore, we would argue for a careful assessment of major and minor clinical features of XLOS patients for a better understanding of the molecular role of the protein in the disease phenotype, which may have important clinical and therapeutic implications.
